4D Molecular Therapeutics reduces workforce 25%, accelerates wet AMD data to H1 2027; CFO resigns

4D Molecular Therapeutics, Inc.

CFO Uneek Mehra resigns effective July 15; remains principal financial officer through September 2025 and Q2 filing.
Phase 3 4FRONT-1 wet AMD trial topline data accelerated to H1 2027 (from H2 2027); 4FRONT-2 started in June 2025.
Workforce reduction of ~25% of current and planned roles in July 2025, primarily early-stage R&D and support functions.
Expected $3M in severance costs in Q3 2025; annual cash compensation savings of ~$15M.
Cash, equivalents and marketable securities of $458M as of March 31, 2025; runway into 2028.

item 5.02item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.